SecBot SecBot
PRESS-RELEASE ·Filed Nov 13, 2026

NSPR

InspireMD Inc.
BEARISH
Impact 6/10
Horizonimmediate Processed4d 8h ago WireGlobeNewswire
Press release · Offering
Actionable Insight ▼ Bearish

Monitor the final prospectus supplement for exact pricing and net proceeds. The company's cash burn rate (Q3 operating expenses $10.2M) suggests this capital raise is critical for near-term survival. Watch for any update on the CGuard Prime for CAS PMA supplement submission timeline and U.S. sales ramp.

DirectionBearish
Confidencehigh
Horizonimmediate

CGuard Prime

◆ Mixed Named in this press release
Impact
Phase
Approved (FDA PMA)
Time to market
CGuard Prime is already FDA-approved and was commercially launched for CAS procedures before the May 2026 recall paused U.S. sales. The new TCAR indication was approved November 12, 2026, and the company plans a U.S. commercial relaunch in Q4 2026 pending FDA approval of the 80cm delivery system.
Next catalyst
NDA filing · Dec 2026

What to watchThe next catalyst is FDA approval of the CGuard Prime 80cm delivery system, anticipated in Q4 2026 (any day now). Approval would enable a fuller U.S. commercial relaunch after the 135cm recall. Separately, the company plans to submit a PMA supplement for an enhanced CGuard Prime for CAS procedures in December 2026. The stock's ~17% drop today reflects the dilutive $37.5M offering, not the TCAR approval itself.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$0.6441
T+0 close · Nov 13, 2026 · via day close
Latest settled
−6.85%
T+1 · $0.6000
Vs SPY
−4.94%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $0.6441entry
  2. T+1 · yesterday −6.85%α −4.94% · $0.6000
  3. T+2 · todayOpen
  4. T+5 · in 3d Pending
  5. T+20 · in 27d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

InspireMD priced a public offering of 7.34M shares, pre-funded warrants for 50.35M shares, and common warrants for 43.27M shares, with an underwriter option for additional securities. The offering follows yesterday's Q3 earnings release showing an 11% revenue decline and a $9.8M net loss, and a preliminary prospectus supplement filed the same day. Proceeds are for R&D, sales, marketing, and working capital.

Key Facts

  • Priced offering of 7,342,308 common shares, pre-funded warrants for 50,350,000 shares, and common warrants for 43,269,231 shares
  • Underwriters have 30-day option to purchase additional 8,653,846 shares and/or pre-funded warrants and/or common warrants for 6,490,384 shares (15% of total)
  • Offering expected to close on or about November 16, 2026
  • Lake Street Capital Markets is sole book-running manager
  • Proceeds to be used for R&D, sales and marketing, working capital, and general corporate purposes
  • Q3 2026 revenue declined 11.1% YoY to $2.24M; net loss of $9.76M
  • Cash and equivalents fell from $54.2M (Dec 2025) to $19.2M (Sep 2026)
  • Market cap is $37M, making the offering highly dilutive relative to current shares outstanding

Financial Impact

Offering includes up to 57.7M shares (common + pre-funded) plus 43.3M common warrants; at $0.80/share (Nov 11 close), gross proceeds could exceed $46M before warrants; dilution is massive relative to current 46M shares outstanding (pre-offering).

dilutioncashworking capital

Risk Factors

  • Extreme dilution: pre-funded warrants alone represent 50.35M shares, more than doubling the current share count
  • Company has substantial doubt about ability to continue as a going concern (stated in risk factors)
  • Q3 revenue decline and cash burn rate indicate ongoing operational challenges
  • Voluntary U.S. recall of CGuard Prime delivery system continues to impact U.S. revenue

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3402557

Track record

29 reports on NSPR

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +54.19% at T+60 after the Apr 3, 2026 report. 9 of 13 went positive at some point.

Filters
  1. Nov 17, 2026today Insider Cluster Mixed 5/10 Entry $0.6500 Now $0.6500 −0.00% settles Feb 17
  2. Nov 16, 20261d ago 8-K Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 12
  3. Nov 16, 20261d ago 424B5 Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 12
  4. Nov 13, 20264d ago Press Release Bearish 6/10 Viewing Entry $0.6441 Now $0.6500 −0.92% settles Feb 11
  5. Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 11
  6. Nov 12, 20264d ago 8-K Bullish 7/10 No price data
  7. Nov 12, 20264d ago 8-K Bullish 6/10 Entry $0.6441 Now $0.6500 +0.92% settles Feb 11
  8. Nov 12, 20265d ago Press Release Bearish 5/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 11
  9. Nov 12, 20265d ago Press Release Bullish 7/10 Entry $0.6441 Now $0.6500 +0.92% settles Feb 11
  10. Nov 12, 20265d ago Press Release Bullish 8/10 Entry $0.6441 Now $0.6500 +0.92% settles Feb 11
Showing 10 of 29

US Market Status

Market Closed · Opens Wed (17h 2m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026